Hypertension in Chronic Kidney Disease: Navigating the Evidence

Overview

Journal Int J Hypertens

Publisher Wiley

Date 2011 Jul 13

PMID 21747971

Citations 57

Authors

F M Tedla

A Brar

R Browne

C Brown

Affiliations

Soon will be listed here.

Abstract

Hypertension is both an important cause and consequence of chronic kidney disease. Evidence from numerous clinical trials has demonstrated the benefit of blood pressure control. However, it remains unclear whether available results could be extrapolated to patients with chronic kidney diseases because most studies on hypertension have excluded patients with kidney failure. In addition, chronic kidney disease encompasses a large group of clinical disorders with heterogeneous natural history and pathogenesis. In this paper, we review current evidence supporting treatment of hypertension in various forms of chronic kidney disease and highlight some of the gaps in the extant literature.

Citing Articles

Plant-Dominant Low-Protein Diets: A Promising Dietary Strategy for Mitigating Disease Progression in People with Chronic Kidney Disease-A Comprehensive Review.

Kaimori J, Sakaguchi Y, Oka T, Isaka Y Nutrients. 2025; 17(4).

PMID: 40004970 PMC: 11857991. DOI: 10.3390/nu17040643.

Global burden of chronic kidney disease due to dietary factors.

Yin L, Kuai M, Liu Z, Zou B, Wu P Front Nutr. 2025; 11:1522555.

PMID: 39882042 PMC: 11774714. DOI: 10.3389/fnut.2024.1522555.

Preventive Effects of Resistance Training on Hemodynamics and Kidney Mitochondrial Bioenergetic Function in Ovariectomized Rats.

Queiroz A, Garcia C, Silva J, Cavalini D, Alexandrino A, Cunha A Int J Mol Sci. 2025; 26(1.

PMID: 39796122 PMC: 11720031. DOI: 10.3390/ijms26010266.

How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease.

Masenga S, Desta S, Hatcher M, Kirabo A, Lee D Curr Res Physiol. 2024; 8:100133.

PMID: 39665027 PMC: 11629568. DOI: 10.1016/j.crphys.2024.100133.

Sympathetic transduction to blood pressure in patients with chronic kidney disease.

Kissell C, Young B, Kaur J, Taherzadeh Z, Mohan P, Vianna L Clin Auton Res. 2024; .

PMID: 39542982 DOI: 10.1007/s10286-024-01084-7.

References

Agarwal R, Nissenson A, Batlle D, Coyne D, Richard Trout J, Warnock D . Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003; 115(4):291-7. DOI: 10.1016/s0002-9343(03)00366-8. View

Chabova V, SCHIRGER A, W Stanson A, McKusick M, Textor S . Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc. 2000; 75(5):437-44. DOI: 10.4065/75.5.437. View

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View

Sarnak M, Greene T, Wang X, Beck G, Kusek J, Collins A . The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005; 142(5):342-51. DOI: 10.7326/0003-4819-142-5-200503010-00009. View

Bangash F, Agarwal R . Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2009; 4(3):656-64. PMC: 2653652. DOI: 10.2215/CJN.05391008. View

Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547-59. DOI: 10.1056/NEJMoa0801317. View

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

Kalra P, Guo H, Kausz A, Gilbertson D, Liu J, Chen S . Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005; 68(1):293-301. DOI: 10.1111/j.1523-1755.2005.00406.x. View

Chapman A, Johnson A, Gabow P, Schrier R . The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med. 1990; 323(16):1091-6. DOI: 10.1056/NEJM199010183231602. View

10.

Blaustein M, Zhang J, Chen L, Song H, Raina H, Kinsey S . The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension. Hypertension. 2008; 53(2):291-8. PMC: 2727927. DOI: 10.1161/HYPERTENSIONAHA.108.119974. View

11.

Vaziri N . Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004; 13(1):93-9. DOI: 10.1097/00041552-200401000-00013. View

12.

Schrier R, Estacio R, Esler A, Mehler P . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61(3):1086-97. DOI: 10.1046/j.1523-1755.2002.00213.x. View

13.

Weidmann P, Maxwell M, Lupu A, Lewin A, Massry S . Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med. 1971; 285(14):757-62. DOI: 10.1056/NEJM197109302851401. View

14.

Snyder J, Collins A . KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol. 2009; 30(1):44-54. DOI: 10.1159/000201014. View

15.

Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View

16.

van Jaarsveld B, Krijnen P, Pieterman H, Derkx F, Deinum J, Postma C . The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000; 342(14):1007-14. DOI: 10.1056/NEJM200004063421403. View

17.

Wheatley K, Ives N, Gray R, Kalra P, Moss J, Baigent C . Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009; 361(20):1953-62. DOI: 10.1056/NEJMoa0905368. View

18.

Muntner P, Judd S, Krousel-Wood M, McClellan W, Safford M . Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis. 2010; 56(3):447-57. PMC: 3659158. DOI: 10.1053/j.ajkd.2010.02.348. View

19.

Vaughan Jr E, Carey R, Ayers C, Peach M . Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme. J Clin Endocrinol Metab. 1979; 48(5):869-71. DOI: 10.1210/jcem-48-5-869. View

20.

Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G . Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2009; 55(3):441-51. PMC: 2866514. DOI: 10.1053/j.ajkd.2009.09.014. View